Key result
Dual pathway inhibition and dual antiplatelet therapy are superior to single antiplatelet therapy with aspirin for atherothrombosis prevention in high-risk patients.
Why the study?
Despite ongoing developments, prevention and treatment of atherothrombotic cardiovascular disease remains a common challenge, requiring personalized antithrombotic therapy selection.
Does dual pathway inhibition or dual antiplatelet therapy prevent atherothrombotic cardiovascular disease in high-risk patients compared to single antiplatelet therapy with aspirin?
Does dual pathway inhibition or dual antiplatelet therapy prevent atherothrombotic cardiovascular disease in high-risk patients compared to single antiplatelet therapy with aspirin?
Antithrombotic therapy should be customized based on patient risk profiles, utilizing DAPT for revascularization-driven risk and DPI for broader atherothrombotic involvement.
Despite ongoing developments, prevention and treatment of atherothrombotic cardiovascular disease remains a common challenge. Antithrombotic options for cardiocerebrovascular disease prevention involves a choice between dual antiplatelet therapy (DAPT) and dual pathway inhibition (DPI), which includes an antiplatelet agent and a reduced dose anticoagulant agent. In selected patients at high risk of event and low risk of bleeding, especially those undergoing recent and complex coronary revascularization using drug-eluting stents (DES) ("revascularization-driven effect"), DAPT is superior to single antiplatelet therapy with aspirin. DPI involves a wider potential range of treatment and is superior to single antiplatelet therapy with aspirin, particularly in patients with atherothrombotic involvement in different vascular beds both previously revascularized and not ("no revascularization-driven effect"). After nearly thirty years of randomized trials and observational registries, we have sufficient data to customize antithrombotic therapy in patients at high cardiovascular risk. Therefore, "atherothrombosis stakeholders" must identify the right patient for the right therapy to ensure high levels of efficacy and safety with the best of current therapeutic opportunities.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a review in atherothrombotic cardiovascular disease. Dual pathway inhibition (DPI) vs. single antiplatelet therapy with aspirin was evaluated. Dual pathway inhibition and dual antiplatelet therapy are superior to single antiplatelet therapy with aspirin for atherothrombosis prevention in high-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: